Research Paper Volume 14, Issue 19 pp 7941—7958
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Figure 5. Expression and prognosis of ERAP2 in pancreatic cancer. (A) Expression of ERAP2 in GSE45452 chip pancreatic tumor and paracancerous tumor. (B) The expression of ERAP2 in extracellular vesicles of blood origin. (C) Expression of ERAP2 in the pancreatic cancer dataset from GEPIA database. (D) Kaplan-Meier survival curve of ERAP2 in pancreatic cancer data set from GEPIA database. (E) Immunohistochemical images of ERAP2 in pancreatic tissues and pancreatic tumors from ProteinAtlas database.